Cargando…

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome

BACKGROUND: There is an urgent need for objective markers of Alzheimer’s disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response to disease-modifying therapies. Previously, GluA4 and neuronal pentraxin 2 (NPTX...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lleó, Alberto, Carmona-Iragui, Maria, Videla, Laura, Fernández, Susana, Benejam, Bessy, Pegueroles, Jordi, Barroeta, Isabel, Altuna, Miren, Valldeneu, Silvia, Xiao, Mei-Fang, Xu, Desheng, Núñez-Llaves, Raúl, Querol-Vilaseca, Marta, Sirisi, Sònia, Bejanin, Alexandre, Iulita, M. Florencia, Clarimón, Jordi, Blesa, Rafael, Worley, Paul, Alcolea, Daniel, Fortea, Juan, Belbin, Olivia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240298/ https://www.ncbi.nlm.nih.gov/pubmed/34183050 http://dx.doi.org/10.1186/s13195-021-00861-0

Ejemplares similares

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
por: Benejam, Bessy, et al.
Publicado: (2020)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
por: Iulita, Maria Florencia, et al.
Publicado: (2022)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
por: Pegueroles, Jordi, et al.
Publicado: (2020)

Evaluation of biochemical and hematological parameters in adults with Down syndrome
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2021)

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
por: Alcolea, Daniel, et al.
Publicado: (2019)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis
por: Dols-Icardo, Oriol, et al.
Publicado: (2020)

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies
por: Querol-Vilaseca, Marta, et al.
Publicado: (2017)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
por: Jimenez, Amanda, et al.
Publicado: (2017)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

Nanoscale structure of amyloid-β plaques in Alzheimer’s disease
por: Querol-Vilaseca, Marta, et al.
Publicado: (2019)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders
por: Delaby, C., et al.
Publicado: (2020)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer’s Disease
por: Giménez, Sandra, et al.
Publicado: (2022)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

AMYQ: An index to standardize quantitative amyloid load across PET tracers
por: Pegueroles, Jordi, et al.
Publicado: (2021)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
por: Illán‐Gala, Ignacio, et al.
Publicado: (2019)

APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
por: Sampedro, Frederic, et al.
Publicado: (2015)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2019)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies
por: Reyes-Leiva, David, et al.
Publicado: (2022)

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration
por: Cervantes González, Alba, et al.
Publicado: (2022)

Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2023)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
por: Altuna, Miren, et al.
Publicado: (2021)

Vamps & tramps /
por: Paglia, Camille, 1947-
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_9b6o7737ef9hrhci1s1dmf300j